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Abstract: Enhancing the oral bioavailability of peptides has received a lot of attention for decades but
remains challenging, partly due to low intestinal membrane permeability. Combining a permeation
enhancer (PE) with unidirectionally releasing microcontainers (MCs) has previously been shown to
increase insulin permeation across Caco-2 cell monolayers. In the present work, this setup was further
employed to compare three common PEs—sodium caprate (C10), sodium dodecyl sulfate (SDS), and
lauroyl carnitine. The concept was also studied using porcine intestinal tissue with the inclusion
of 70 kDa fluorescein isothiocyanate-dextran (FD70) as a pathogen marker. Moreover, a combined
proteolysis and Caco-2 cell permeation setup was developed to investigate the effect of soybean
trypsin inhibitor (STI) in the MCs. Lastly, in vivo performance of the MCs was tested in an oral gavage
study in rats by monitoring blood glucose and insulin absorption. SDS proved to be the most potent
PE without increasing the ex vivo uptake of FD70, while the implementation of STI further improved
insulin permeation in the combined proteolysis Caco-2 cell setup. However, no insulin absorption in
rats was observed upon oral gavage of MCs loaded with insulin, PE and STI. Post-mortem microscopic
examination of their gastrointestinal tract indicated lack of intestinal retention and optimal orientation
by the MCs, possibly precluding the potential advantage of unidirectional release.
Keywords: oral peptide delivery; microdevices; permeation enhancers; protease inhibitors; Caco-2
cells; Franz diffusion cells; oral gavage
1. Introduction
Since the discovery of insulin, almost a century ago, there has been a profound pursuit of
developing strategies for oral peptide administration in order to improve patient convenience [1–4].
Many of the approaches reaching clinical trials have been based on combining enteric coatings,
protease inhibitors and permeation enhancers (PEs) to ensure gastric and enzymatic protection
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while improving intestinal absorption [2,4,5]. For overcoming the absorption barrier, PEs have been
developed and studied both for paracellular enhancement by tight junction opening and transcellular
enhancement for example by perturbation of the enterocyte cell membranes [6]. Recently, the
commercial potential using PEs was further cemented with approval by the U.S. Food and Drug
Administration of the glucagon-like peptide-1 (GLP-1) agonist, semaglutide, for oral administration
based on gastric permeation enhancement by salcaprozate sodium (SNAC) [7]. While commercialization
has proved achievable with an oral bioavailability of 0.1–1.2% for peptides such as desmopressin and
semaglutide [7,8], there still lies an obvious potential in further improving the fraction of intact peptide
absorption. This could lead to lower manufacturing expenses or simply enabling the therapeutic
availability of larger macromolecules more prone to degradation in the gastrointestinal (GI) tract.
The recent discontinuation of an oral dosage form development of insulin using the PE, sodium
caprate (C10), confirms this potential as it was deemed commercially unviable due to the high doses
required, despite glycemic control similar to subcutaneously administered insulin [9]. The need for
high doses is linked to both enzymatic degradation of insulin and diffusion-driven dilution from the
site of tablet disintegration, decreasing the co-localization of insulin and C10. Evidence from studies
of PE-technologies suggests that simultaneous release of PE and peptide is essential for absorption
enhancement by creating a local environment of high co-localized concentrations [7,10].
Unidirectionally releasing microdevices have previously been proposed to ensure co-localization of
drug and excipients, while simultaneously minimizing the required amount of drug formulation [11–13].
Different fabrication technologies have realized a range of such microdevices capable of protecting the
drug formulation from the harsh environment in the GI tract until release at the site of absorption [14].
Manufacturing of microcontainers (MCs) has been investigated by several different techniques such
as photolithography, hot embossing and mechanical punching resulting in cylindrical reservoirs
of 200–300 µm in both height and diameter [15–17]. Results from intestinal perfusion studies have
indicated spontaneous entanglement of MCs in intestinal mucus, thereby facilitating intestinal retention
and thus potentially confining the area of drug absorption [18]. Enhanced local effects of C10 together
with steep insulin concentration gradients across Caco-2 cell monolayers were recently studied using
MCs with fixed optimal unidirectional release towards the cell monolayers [12]. By controlling the
distance between MCs and the monolayer, by use of custom-made stands, it was evident that close
proximity between the absorptive barrier and the point of release from the MCs is a prerequisite to
achieve C10-enhanced permeation of insulin [12].
Figure 1 represents a schematic overview of the different studies described in the current work.
The initial aim was to extend the previously mentioned distance-controlled in vitro insulin permeation
studies across Caco-2 cell monolayers to compare the effect of three common PEs; C10, sodium dodecyl
sulfate (SDS) and lauroyl (C12) carnitine. Further, the potential of loading a protease inhibitor into
the MCs was assessed in an in vitro setup combining proteolysis with the barrier properties of Caco-2
cell monolayers. Next, the advantage of unidirectional release was tested in a more physiologically
relevant permeation setup by using porcine intestinal tissue and placing PE:insulin loaded MCs on the
tissue, in the presence of an apical pathogen marker. Finally, oral in vivo studies were conducted in
rats in order to evaluate whether previously published indications on intestinal retention of MCs [18]
were sufficient for creating local intestinal environments of high PE and insulin concentrations, leading
to the increased oral bioavailability of insulin.
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Figure 1. Schematic overview of the studies carried out using microcontainers (MCs). (a) In vitro 
permeation studies of insulin across Caco-2 cell monolayers. SDS: sodium dodecyl sulfate, C10: 
sodium caprate, C12-carnitine: lauroyl carnitine, STI: soybean trypsin inhibitor, MCC: 
microcrystalline cellulose, TEER: transepithelial electrical resistance, RP-HPLC: reversed-phase 
high-performance liquid chromatography, and MTS/PMS: metabolic viability assay. (b) Ex vivo 
permeation study across porcine intestinal tissue in a Franz diffusion cell setup (illustration edited 
with permission by PermeGear (Hellertown, PA, USA)). FD70: 70 kDa fluorescein 
isothiocyanate-dextran, ELISA: enzyme-linked immunosorbent assay, and SEC: size exclusion 
chromatography. (c) In vivo oral gavage studies of coated MCs in a gelatin capsule. 
2. Materials and Methods 
2.1. Materials 
Single-side-polished Silicon (Si) wafers (N type doping) were acquired from Okmetic (Vantaa, 
Finland) while the SU-8 constituents (SU-8 2075 and SU-8 Developer) were obtained from Micro 
Resist Technology (Berlin, Germany). All the following reagents were purchased from 
Sigma-Aldrich (St. Louis, MO, USA): insulin (human recombinant), sodium dodecyl sulfate (SDS), 
Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin-streptomycin, L-glutamine (200 mM), 
non-essential amino acid solution (NEAA, 100×), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic 
acid (HEPES), bovine serum albumin (BSA), α-chymotrypsin from bovine pancreas, 
N-benzoyl-L-tyrosine ethyl ester (BTEE), 70 kDa fluorescein isothiocyanate-dextran (FD70) and 
dibutyl sebacate. n-Capric acid sodium salt (C10) was procured from abcr (Karlsruhe, Germany) and 
fetal bovine serum (FBS) from PAA Laboratories (Pasching, Austria). Trifluoroacetic acid (TFA) was 
Figure 1. Schematic overview of the studies carried out using microcontainers (MCs). (a) In vitro
permeation studies of insulin across Caco-2 cell monolayers. SDS: sodium dodecyl sulfate, C10:
sodium caprate, C12-carnitine: lauroyl carnitine, STI: soybean trypsin inhibitor, MCC: microcrystalline
cellulose, TEER: transepithelial electrical resistance, RP-HPLC: reversed-phase high-performance liquid
chromatography, and MTS/PMS: metabolic viability assay. (b) Ex vivo permeation study across porcine
intestinal tissue in a Franz diffusion cell setup (illustration edited with permission by PermeGear
(Hellertown, PA, USA)). FD70: 70 kDa fluorescein isothiocyanate-dextran, ELISA: enzyme-linked
immunosorbent assay, and SEC: size exclusion chromatography. (c) In vivo oral gavage studies of
coated MCs in a gelatin capsule.
.
2.1. Materials
Single-side-polished Silicon (Si) wafers (N type doping) were acquired from Okmetic (Vantaa,
Finland) while the SU-8 constituents (SU-8 2075 and SU-8 Developer) were obtained from Micro
Resist Technology (Berlin, Germany). All the following reagents were purchased from Sigma-Aldrich
(St. Louis, MO, USA): insulin (human recombinant), sodium dodecyl sulfate (SDS), Dulbecco’s Modified
Eagle’s Medium (DMEM), penicillin-streptomycin, l-glutamine (200 mM), non-essential amino acid
solution (NEAA, 100×), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), bovine serum
albumin (BSA), α-chymotrypsin from bovine pancreas, N-benzoyl-l-tyrosine ethyl ester (BTEE), 70 kDa
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fluorescein isothiocyanate-dextran (FD70) and dibutyl sebacate. n-Capric acid sodium salt (C10)
was procured from abcr (Karlsruhe, Germany) and fetal bovine serum (FBS) from PAA Laboratories
(Pasching, Austria). Trifluoroacetic acid (TFA) was purchased from Carl Roth (Karlsruhe, Germany),
VIVAPUR® 101 microcrystalline cellulose (MCC) from JRS Pharma (Rosenberg, Germany) and fasted
state simulated intestinal fluid (FaSSIF) powder from Biorelevant (London, UK). Eudragit® L 100 was
obtained from Evonik (Essen, Germany), lauroyl-dl-carnitine chloride (C12-carnitine) was acquired
from Chemos (Aldorf, Germany) and hard gelatin capsules, size 9, from Torpac® (Fairfield, NJ, USA).
Hanks’ Balanced Salt Solution with calcium and magnesium but without phenol red (HBSS), sodium
bicarbonate solution and soybean trypsin inhibitor (STI) powder were bought from Thermo Fisher
Scientific (Waltham, MA, USA). Cell viability assay constituents (phenazine methosulfate (PMS) and
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS))
were purchased from Promega (Madison, WI, USA). Water used throughout the studies was purified
by an Ultra Clear UV system (Evoqua Water Technologies, Pittsburgh, PA, USA).
2.2. Microcontainer Fabrication, Characterization, Drug Loading and Polymer Coating
SU-8 MCs were fabricated by a two-step photolithography process on Si wafers and subsequently
diced into chips (12.8 × 12.8 mm2), with each holding 625 MCs, as previously described [15]. MCs used
for in vitro and ex vivo studies were developed directly on Si wafers where detachment of individual
MCs was not needed. To ensure easy harvest of the MCs for in vivo studies, the MCs were produced
on Si wafers with a dedicated release layer made by electron beam deposition of 5 nm of titanium
and 20 nm of gold. The dimensions of the MCs on each wafer were determined with an Eclipse L200
bright-field optical microscope (Nikon, Tokyo, Japan) for evaluating the inner and outer diameters,
while the inner and overall heights of the MCs were measured by vertical scanning interferometry
using a PLu Neox 3D Optical Profiler (Sensofar, Terrassa, Spain). Insulin formulations were loaded as
powder mixtures by centrifugal compaction, as described earlier [12]. Furthermore, MCs, loaded for
in vivo studies, were sealed with a lid on the opening. This was performed by spray coating a solution
of 1% (w/v) Eudragit® L 100 and 0.54% (v/v) dibutyl sebacate in isopropanol using an ExactaCoat
Ultrasonic Spray System (Sono-Tek, Milton, NY, USA) with an infuse rate of 0.05 mL/min, path speed
of 5 mm/s and shaping air of 0.02 mbar. In addition, the generator power was set to 2.2 W and an
AccuMist nozzle with a spray distance of 50 mm was utilized. Detachment of MCs from the Si-chip for
the in vivo studies was carried out with a plastic spatula before loading them into gelatin capsules
(size 9) using a ProFunnel (Torpac®, Fairfield, NJ, USA). Visualization of the coating and the MCs was
carried out by scanning electron microscopy (SEM) both before and after detachment of the Si-chip
using a Hitachi TM3030 tabletop microscope (Hitachi High-Technologies Europe, Krefeld, Germany)
with an accelerating voltage of 15 kV. The loaded gelatin capsule for oral administration was captured
with a Dino-Lite Premier AM7013MZT digital microscope (AnMo Electronics Corporation, Taiwan).
2.3. In Vitro Permeation Studies
Insulin permeation was monitored from the apical (1.50 mL) to the basolateral (2.60 mL)
compartment across 4.67 cm2 polycarbonate Transwell® filters (Corning, Corning, NY, USA) seeded
with Caco-2 cells (American Type Culture Collection, Manassas, VA, USA). Cell culturing was done in
DMEM supplemented with FBS (10%, v/v), l-glutamine (2 mM), penicillin (100 U/mL), streptomycin
(100 µg/mL) and NEAA (1%, v/v) for 21–23 days at 37 ◦C and 5% CO2 with a final density of
1 × 105 cells/cm2. Three different PEs (SDS, C10, or C12-carnitine) were loaded into one chip of MCs
together with insulin in a 1:4 weight ratio (PE:insulin). The transepithelial electrical resistance (TEER) of
the Caco-2 cell monolayers was measured upon equilibration to room temperature using an Epithelial
Volt/Ohm Meter (World Precision Instruments, Sarasota, FL, USA) with Endohm™ chambers. First
recording took place in culture medium prior to the permeation study; after which, the monolayers
were washed twice with permeation buffer consisting of 10 mM HEPES in HBSS (hHBSS) supplied with
BSA (0.05%, w/v), NaHCO3 (0.38%, w/v) and adjusted to pH 7.4. Insulin permeation was monitored
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for each PE:insulin mixture either loaded into MCs with close contact to the Caco-2 cell monolayer
or at a distance of 0.5 mm achieved with custom-made teflon stands as previously described [12].
All three PE:insulin combinations were also tested as solutions of amounts equivalent to the loading
capacity of the MC chips (0.6–1.1 mM PE, 0.15 mM insulin) in combination with a chip of empty MCs
placed directly on the Caco-2 cell monolayer. Each of the three different studies per PE was carried
out in triplicates and across three passages with all studies conducted within eight passages. Insulin
permeation was monitored over 2 h at 37 ◦C and 75 rpm orbital shaking (Compact Shaker KS 15 A,
Edmund Bühler, Bodelhausen, Germany) with 100 µL basolateral sampling at 15, 30, 45, 60, 90 and
120 min, and each sampling replaced with 100 µL preheated (to 37 ◦C) hHBSS. The MC chips were
then removed from the Caco-2 cell monolayers, followed by washing twice with hHBSS before TEER
was recorded again. Insulin concentrations in the basolateral samples were immediately quantified by
reversed-phase high-performance liquid chromatography (RP-HPLC).
2.4. Combined In Vitro Permeation and Proteolysis
The effect of various STI concentrations (0, 12, 30, 60 and 120 µg/mL) on α-chymotrypsin inhibition
was initially assessed in insulin digestion studies with fixed concentrations of insulin (600 µg/mL)
and α-chymotrypsin (10 µg/mL) in FaSSIF buffer at 37 ◦C. Samples of 240 µL were mixed with 60 µL
aqueous TFA solution (5%, v/v) at 0, 5, 10, 20, 40, 60, 90 and 120 min and analyzed by RP-HPLC to
determine the fraction of remaining native insulin. The compatibility of integrating proteolysis in the
in vitro permeation setup was then tested by measuring TEER and viability as the metabolic activity
of Caco-2 cell monolayers after 2 h of apical exposure to different concentrations of α-chymotrypsin
(0, 10, 50 and 100 µg/mL) in hHBSS. Viability was determined after washing the cells with fresh
hHBSS followed by the apical addition of 1.5 mL freshly made MTS (240 µg/mL) and PMS solution
(2.4 µg/mL) in hHBSS before incubation in dark conditions for 1.5 h with 75 rpm orbital shaking at
37 ◦C. The absorbance at 492 nm of three 100 µL samples from each well was measured in a 96-well
plate using a Multiskan MS 352 Microplate Reader (Labsystems, Helsinki, Finland). Proteolysis was
finally incorporated in the in vitro permeation study by the addition of α-chymotrypsin (10 µg/mL)
to the apical compartment in an otherwise identical protocol as described in Section 2.3. The only
difference was the immediate chymotrypsin inhibition of each basolateral sample by mixing with 25 µL
aqueous TFA solution (5%, v/v). All MC chips were loaded with fixed insulin and SDS amounts of 60%
and 20% (w/w), respectively. The remaining 20% was made up of either STI or MCC.
2.5. Ex Vivo Intestinal Permeation Studies
The jejunum and ileum were collected from an anaesthetized pig (approx. 40 kg) immediately
before it was euthanized. As the animal was placed under anesthesia and euthanized for a different
purpose, no ethical approval was necessary for retrieval of the tissue. Intestinal segments of 10–20 cm
were prepared and stored at −20 ◦C until the day of the permeation study. Prior to the study, a segment
was thawed in 10 mM HEPES-buffered DMEM (hDMEM) and longitudinally cut open. Luminal
contents were washed away with hDMEM and the muscularis was removed using tweezers before the
mucosa was cut into 4 × 4 cm pieces and placed in Franz diffusion cells. Each receptor compartment
was filled with 7 mL of hDMEM facing the serosal side of the intestinal tissue. The donor side, facing
the mucosa, was filled with 1.5 mL FD70 solution (100 µg/mL) in hDMEM to imitate the inclusion of a
pathogen. Permeation was initiated by placing a chip of loaded MCs directly on top with the openings
facing the mucosa. Similar to the in vitro permeation study, PE:insulin-loaded MCs were compared to
a solution of equivalent amounts of insulin and PE in combination with a chip with empty MCs. Chips
with MCs loaded with insulin alone were also included as an additional control group. Insulin and
FD70 permeation were monitored over 3 h, with sampling from the receptor compartment at 0, 15,
30, 45, 60, 90, 120 and 180 min with each sampling replaced with an equivalent volume of hDMEM.
Quantification of insulin and FD70 was carried out by enzyme-linked immunosorbent assay (ELISA)
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as described by the supplier (Mercodia, Uppsala, Sweden) and size exclusion high-performance liquid
chromatography (SEC-HPLC), respectively.
2.6. In Vivo Studies
Male Sprague–Dawley rats (Janvier Labs, Le Genest-Saint-Isle, France) were housed in groups of
six per cage and allowed to acclimatize for at least one week with a reversed 12/12 h day/night cycle.
Fasting of the rats was initiated 12–14 h prior to the studies, with ad libitum access to water. The
rats were 6–7 weeks old and weighed 288 ± 26 g (n = 18) on the day of the studies. The experiments
were carried out in concordance with the Danish law on animal experiments as approved by the
Danish Animal Experiments Inspectorate in accordance with the EU directive 2010/63/EU under license
number 2016-15-0201-00892 (25 April 2016). The study was designed with four groups including
negative and positive controls receiving subcutaneous (SC) injections of saline or insulin solution
(1 IU/kg), respectively, and both oral gavage of empty gelatin capsules. The remaining two groups
received SC saline injections and oral gavage of capsules loaded with Eudragit® L 100-coated MCs
filled with insulin:PE:STI powder mixtures (6:2:2, w/w/w) using either SDS or C10 as the PE. Blood
samples of 200 µL were drawn from the tail vein into Microvette® 200 K3E tubes (Sarstedt, Nümbrecht,
Germany) at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Blood glucose concentrations were determined
immediately with a Contour® XT meter (Ascensia Diabetes Care, Basel, Switzerland) before isolating
the blood plasma by centrifugation at 9300× g for 10 min at 4 ◦C in a Microcentrifuge 5415 R (Eppendorf,
Hamburg, Germany). Plasma samples were then stored at −20 ◦C until insulin quantification by ELISA
(Mercodia, Uppsala, Sweden). Euthanasia of the rats was done in a CO2 gassing chamber; after which,
the stomachs and small intestines were removed from two of the rats that had been administered
MCs in order to localize their position and orientation by fluorescence microscopy, as described in a
previous study [19].
2.7. HPLC Quantification of Insulin and FD70
A Dionex Ultimate 3000 system (Thermo Fisher Scientific, Waltham, MA, USA) was used for all
HPLC analyses of insulin with an injection volume of 20 µL and a column temperature at 22 ◦C. All
insulin samples were quantified as the area under the curve (AUC) of the UV absorbance peak at
214 nm, each time using a new standard curve from 2–100 µg/mL. In vitro permeation samples without
proteolysis were separated on a Kinetex XB-C18 column (100 × 4.6 mm, 5 µm, 100 Å; Phenomenex,
Torrance, CA, USA), with two mobile phases of A: 0.1% (v/v) TFA in water and B: 0.1% (v/v) TFA in
acetonitrile. The following gradient was applied with a flow rate of 0.5 mL/min: 0–0.5 min A:B (80:20,
v/v), 0.5–5.5 min A:B (80:20 to 40:60, v/v), 5.5–6 min A:B (40:60, v/v), 6–6.5 min A:B (40:60 to 80:20, v/v)
and 6.5–8 min A:B (80:20, v/v). Samples involving proteolysis were separated on a Luna C18 column
(150 × 4.6 mm, 5 µm, 100 Å; Phenomenex, Torrance, CA, USA) with the same two mobile phases using
a flow rate of 1.0 mL/min with the following gradient: 0–1.5 min A:B (75:25, v/v), 1.5–11 min A:B (75:25
to 60:40, v/v), 11–12 min A:B (60:40 to 20:80, v/v), 12–13 min A:B (20:80 to 75:25, v/v) and 13–15 min A:B
(75:25, v/v). FD70 in the ex vivo permeation samples was quantified as the AUC of the fluorescence
emission signal of 518 nm with excitation of 492 nm using freshly prepared standards (5–100 ng/mL
range) for every analysis. Separation was achieved on a BioSep SEC-s2000 column (300 × 7.8 mm, 5 µm,
145 Å, Phenomenex, Torrance, CA, USA) equipped with a PolySep GFC-P Guard column (35 × 7.8 mm,
Phenomenex, Torrance, CA, USA) with a 10 mM phosphate buffer at pH 7.0 as isocratic mobile phase
with a flow rate of 1.0 mL/min and a run time of 45 min.
2.8. Data Analysis
All data were processed using Microsoft Excel 2010 (Redmond, WA, USA) and GraphPad Prism
version 8.2.1 (San Diego, CA, USA) and expressed as the mean ± standard deviation (SD) unless
otherwise stated. For cell studies, n, determines the number of passages with each passage run
in triplicates.
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3. Results and Discussion
3.1. Microcontainer Fabrication and Characterization
MCs fabricated on Si wafers had average outer and inner diameters of 323.2± 1.7 and 235.3± 1.9µm,
respectively, calculated as the averages of 24 measurements across three wafers by optical microscopy.
Overall and inner heights were 250.1 ± 3.1 and 214.0 ± 4.0 µm, respectively, determined with an optical
profiler, corresponding to an average loading volume of 9.3 nL per MC.
3.2. In Vitro Permeation Studies
MC chips were loaded with PE (C10, SDS or C12-carnitine) and insulin at a 1:4 w/w ratio. The
powder mixtures corresponded to an average loading of 1285 µg insulin and 321 µg PE per MC chip
determined by the weight of added powder mixture and insulin quantification by RP-HPLC. Control
solutions of each PE:insulin powder mixture, equivalent to the loading capacity of the MC chips, were
included in the study in combination with empty MC chips. In this way, all permeation studies were
based on equivalent amounts of insulin and PEs. In addition, all Caco-2 cell monolayers were exposed
to the presence of MC chips. The results of both TEER and insulin permeation measurements for each
study condition are shown in Figure 2.
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permeation buffer. Absolute mean value of initial TEER was 467± 34Ω cm2 (n = 7). * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001, and ns: not significant, based on Tukey’s m ltiple comparisons one-way
ANOVA test comparing TEER after unidirectional release from 0.0 and 0.5 mm with respective solutions
and comparing the solutions with the control. (b) Accumulated insulin permeation profi es over time.
: 0.0 mm, : 0.5 mm, N: solution, blue: SDS, red: C12-carnitine, a d green: C10. **** p < 0.0001 based
on linear regression analysis y compari g the SDS permeation profiles with the respective r eation
profiles of C10 and C12- arnitine. D ta are shown as the mean + SD (n = 3).
Confinement of insulin and PE in MCs had significant effects on both TEER values and insulin
permeation for all three PEs compared to their respective solutions. As the presence of empty MC
chips is not leading to similar insulin permeation, the effect must be due to local high concentrations
of insulin and PE. The effect of local high PE concentrations on the monolayer under the opening
of C10-releasing MCs has previously been visualized by laser-scanning confocal microscopy of cell
monolayers cultured on Transwell® filters [12]. Furthermore, we have previously shown that the
onolayers, upon local disruptions caused by C10-release from MCs, were able to regain almost 90%
of initial integrity within 24 h [12]. In the present study, SDS was a significantly more potent PE
when compared to C10 and C12-carnitine, based on the insulin permeation rates. This is in agreement
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with previous studies where SDS concentrations as low as 0.40 mM resulted in immediate loss of
epithelial integrity, while concentrations of C10 inducing in vitro permeation usually are in the order of
10 mM [20–22]. In comparison, the PE solutions used as controls in the present study were 0.6, 0.7 and
1.1 mM of C12-carnitine, SDS and C10 respectively. However, the higher potency of SDS also comes
with a higher risk of cell toxicity as studies showed that 2 h exposure to 0.40 mM SDS resulted in
irreversible deterioration of barrier integrity [21]. The complete loss of monolayer integrity (>95%)
when subjected to SDS:insulin-loaded MCs strongly indicates that a substantial number of cells have
been washed off the filter. Whether these conditions would result in similar insulin permeation profiles
across the more complex intestinal barrier, and if PE-induced pathogen absorption could be a risk, was
assessed in the following ex vivo setup.
3.3. Ex Vivo Intestinal Permeation Studies
As for the in vitro permeation studies, MC chips were initially loaded with PE (SDS or C10) and
insulin at a 1:4 w/w ratio for the ex vivo Franz diffusion cell setup. Comparison was thus only done
between C10, which had shown equal in vitro potency to C12-carnitine, and SDS, which had resulted in
significantly higher insulin permeation in vitro. Control solutions corresponding to each PE:insulin
powder mixture (1:4, w/w), (equivalent to the loading capacity of the MC chips), were also included in
this study together with an empty MC chip placed directly on the tissue. Furthermore, two additional
SDS:insulin ratios (1:1 and 1:8, w/w) were loaded into MCs to evaluate the potential of optimizing
the ratio of SDS and insulin. MCs only loaded with insulin were assessed as a negative control. All
insulin permeation profiles across porcine intestinal tissue are shown in Figure 3 together with the
corresponding FD70 permeation profiles.
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permeation was observed by the MCs without PE. The insulin permeation depends on the interplay 
between the PE concentration and the insulin concentration gradient experienced by the barrier. An 
insufficient amount of SDS when loading 1:8 (SDS:insulin, w/w) could thereby explain the decrease 
in insulin permeation compared to MCs loaded with 1:4 (SDS:insulin, w/w). On the other hand, 
decreasing the insulin concentration gradient across the tissue is likely counteracting the 
presumably increased effect of SDS, thereby causing lower insulin permeation when loading MCs 
with 1:1 compared to 1:4 (SDS:insulin, w/w). Although, none of the tissue barriers were capable of 
Figure 3. (a) Accumulated insulin permeation profiles across porcine intestinal tissue in a Franz
diffusion cell setup in buffered Dulbecco’s Modified Eagle’s Medium at 37 ◦C, : loaded MCs with
indicated PE:insulin w/w ratios, N: solution of PE and insulin (1:4, w/w). **** p < 0.0001 based on linear
regression analysis by comparing the slope from 60–180 min of the permeation profile of MCs loaded
with SDS:insulin (1:4, w/w) with the respective permeation profile of loaded MCs with C10:insulin (1:4
w/w); (b) Accumulated FD70 permeation profiles shown as percentages of a total amount of apically
applied 150 µg of dissolved FD70. Data are shown as the mean − SD (n = 3).
for the in vitro permeation studies, SDS also resulted in significantly h gher insulin p meatio
across the por ine intestinal tissue comp red with C10. However, a decrease in insulin p rmeatio was
seen for the additional tw SDS:insulin ratios (1:1 and 1:8), and no n ulin permeation was observed by
the MCs without PE. The insulin permeation depends on the interplay betwe n the PE conce tration
and th insulin concentration gradient experien ed by he barrier. An insuffic t amount of SDS whe
loading 1:8 (SDS:i sulin, w/ ) could thereby expla the decrease in insulin perme tion compared
to MCs load d with 1:4 (SDS:insulin, w/w). On the other hand, decreasing the insulin concentration
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gradient across the tissue is likely counteracting the presumably increased effect of SDS, thereby
causing lower insulin permeation when loading MCs with 1:1 compared to 1:4 (SDS:insulin, w/w).
Although, none of the tissue barriers were capable of completely retaining FD70 in the donor chamber,
no significant differences were observed between any of the FD70 permeation profiles, indicating that
the PE exposure did not result in deterioration to a level that allowed for the absorption of pathogens.
The Franz diffusion cell setup was chosen as it was optimal for studying unidirectional release on
a horizontal barrier. Ussing chambers have previously been used to study lysozyme permeation
enhancement by MCs across intestinal tissue [23]. However, the vertical barrier would constitute a
challenge regarding controlling the orientation of the MCs. An advantage of the Ussing chamber,
however, is the possibility of prolonging tissue viability by using a Krebs-Ringer bicarbonate buffer
with a continuous flow of oxygen supply by O2:CO2 [24]. Storing the tissue samples at −20 ◦C might
have had an impact on their viability and integrity caused by intracellular ice crystal formation [25],
and thus FD70 was included as integrity marker. However, previous studies have shown equivalent
viabilities between fresh and snap freeze-thawed colorectal tissue samples, yet with poor preservation
of integrity [26]. The tissue preparation, including luminal rinsing, might have further reduced the
proteolytic activity due to the removal of luminal proteases. Therefore, the development of a simple
combined in vitro permeation study with controlled proteolysis was carried out to evaluate the effect
of combining permeation enhancing and protease inhibitory excipients in the MCs.
3.4. Combined In Vitro Permeation and Proteolysis
α-Chymotrypsin activity was initially determined as 48.5 U/mg, following the procedure for
enzymatic assay using BTEE as a substrate as described by the supplier [27]. Caco-2 cell monolayers
were then exposed to different concentrations of α-chymotrypsin for the assessment of compatibility of
combining permeation and proteolysis studies. TEER measurements and the relative viability of the
monolayers after a 2 h exposure are shown in Figure 4.
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Previous studies have described similar findings when subjecting Caco-2 cell monolayers to different
pr teolytic enzym s and further documented the reversibility of this eff ct [28]. For these reasons,
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studies to determine the effect of STI on inhibiting insulin digestion by α-chymotrypsin were initiated.
Based on the previously published average loading capacity of 1.2 mg per MC chip [12] (equal to
960 µg of insulin with a 1:4 (w/w) PE:insulin loading); insulin concentrations were fixed at 600 µg/mL
for all initial digestion studies, corresponding to complete release from the MCs in an apical volume
of 1.50 mL. The concentration of α-chymotrypsin was set at 10 µg/mL (0.49 U/mL), based on the
suggested ratio of α-chymotrypsin:peptide (1:60, w/w) for peptide digestion studies by the supplier, as
well as previously published work on insulin digestion using a similar amount of α-chymotrypsin
(8 µg/mL) [29,30]. Insulin digestion profiles with the addition of different STI concentrations are shown
in Figure 5.
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of proteases, the absorption-enhancing effect as a result of protease inhibition by STI is clearly 
observed. Only approximately 20% native insulin is remaining after 45–60 min in the initial 
digestion study (Figure 5), which is at the same time interval that insulin permeation ceases for the 
group without STI (Figure 6). Concurrently, the insulin gradient is maintained for the group 
Figure 5. Digestion profiles of insulin (60 µg/mL) by α-chymotrypsin (0.49 U/mL) in fasted state
simulated intestinal fluid (FaS IF) at 37 ◦C with different concentrations of STI. Orange: 0 µg/mL,
purple: 12 µg/mL, green: 30 µg/mL, red: 60 µg/mL and blue: 120 µg/mL. Dat are shown as the mean +
SD (n = 3).
Inhibition of α-chymotrypsin was observed even with the addition of only 12 µg/mL of STI,
equivalent to 2% (w/w) relative to insulin, yet more than 90% of native insulin was still degraded
after 2 h. With the addition of 120 µg/mL of STI, corresponding to 20% (w/w) relative to insulin, only
13% digestion was observed over 2 h. Therefore, a combined permeation and proteolysis study was
initiated with MCs loaded with equivalent amounts of SDS (20%, w/w) as in the in vitro permeation
studies, and 20% (w/w) of either STI or MCC, leaving 60% (w/w) filling capacity of the containers left
for insulin loading. The distance between Cs and the monolayer was fixed at 0.5 mm to allow for
better insulin accessibility by α-chymotrypsin, resulting in the permeation profiles shown in Figure 6.
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Despite the simplicity of the in vitro model, only accounting for one type of cells and one type of
proteases, the absorption-enhancing effect as a result of protease inhibition by STI is clearly observed.
Only approximately 20% native insulin is remaining after 45–60 min in the initial digestion study
(Figure 5), which is at the same time interval that insulin permeation ceases for the group without
STI (Figure 6). Concurrently, the insulin gradient is maintained for the group including STI resulting
in a 3.4-fold higher insulin transport after 2 h than without STI. Almost all the insulin was digested
on the apical side after 2 h in the absence of protease inhibition, while the presence of STI evidently
allowed for further insulin uptake (Figure 6). Since the results obtained from the in vitro and ex vivo
studies were all obtained with fixed optimal unidirectional release from the MCs, an in vivo study
was necessary to evaluate whether the intestinal retention and orientation of MCs in the GI tract were
sufficient to achieve absorption of insulin upon oral administration.
3.5. In Vivo Studies
After loading of MCs with insulin:SDS:STI or insulin:C10:STI (both 6:2:2, w/w/w) and coating the
openings of the MCs with Eudragit® L 100, visualization of the coating thickness and the MCs was
carried out as shown in Figure 7a–c. The final dosage form for oral gavage, a size 9 gelatin capsule
filled with coated MCs, is shown in Figure 7d.
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The total insulin doses in the size 9 capsules were determined from the loaded mass per capsule 
and by weighing MC chips before and after detachment giving an average weight of 18.82 µg per 
coated MC. Based on these calculations; the rats were orally administered 673 ± 20 MCs 
corresponding to 104 ± 8 IU/kg of insulin and 1.20 ± 0.09 µg/kg of both PE and STI. Figure 8 shows 
the change in blood glucose measured over 4 h for the two groups receiving MCs by oral gavage and 
for the negative and positive controls receiving SC injections of saline and insulin in saline (1 IU/kg), 
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Figure 7. (a) Scanning electron microscopy (SEM) image of part of a Si-chip with Eudragit® L 100
coated MCs; (b) SEM image of detached MCs; (c) SEM image of the coating (thickness approximately
19 µm); (d) Micrograph of a size 9 gelatin capsule filled with coated MCs.
The total insulin doses in the size 9 capsules were determined from the loaded mass per capsule
and by weighing MC chips before and after detachment giving an average weight of 18.82 µg per
coated MC. Based on these calculations; the rats were orally administered 673 ± 20 MCs corresponding
to 104 ± 8 IU/kg of insulin and 1.20 ± 0.09 µg/kg of both PE and STI. Figure 8 shows the change in
blood glucose measured over 4 h for the two groups receiving MCs by oral gavage and for the negative
and positive controls receiving SC injections of saline and insulin in saline (1 IU/kg), respectively.
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Figure 8. Change in blood glucose in rats over 4 h after oral gavage of MCs loaded with insulin
(104 IU/kg), STI and either C10 or SDS compared to subcutaneous (SC) injections of either saline or
insulin in saline (1 IU/kg). Data are shown as the mean ± standard error of the mean (n = 4–5).
Neither the change in blood glucose nor detection of insulin by ELISA showed any signs of
insulin absorption from the MCs. Previous studies in Caco-2 cell monolayers clearly showed that
close proximity between MCs and the epithelial barrier is a necessity in order to enable permeation
enhancement of insulin even with fixed optimal unidirectional release [12]. While the ex vivo intestinal
permeation studies showed the potential of unidirectional release for permeation enhancement across
intestinal tissue, this effect was not observed in vivo. Fluorescent microscopic examination of the
stomachs and small intestines of the rats after the in vivo study revealed that all MCs had undergone
complete transit from ileum to caecum after 4 h, which is consistent with another recent study of
biodegradable MCs [31]. Previous studies have shown SU-8 MCs embedded in the intestinal mucus in
in situ intestinal perfusion studies [18]. However, the present study could not confirm this behavior.
Instead the in vivo data indicate that the MCs do not achieve sufficient intestinal retention and
orientation necessary for realizing insulin absorption. The need for optimizing the in vivo behavior of
MCs is further substantiated when considering the aspect of drug loading capacity, as the loaded drug
formulation accounts for only 14% of the total weight of a coated MC. Thereby, the effect gained from
the unidirectional release must increase bioavailability by more than 7-fold in order to advantageously
compensate for the additional drug formulation, which could be fitted in a capsule by excluding the
spatial limitation of the MC-material. Current work is therefore looking into improving both intestinal
orientation and retention by structural designs, surface engineering and functional polymer coatings
of the MCs, which might eventually make it possible to increase the oral bioavailability of insulin and
other macromolecules [19,23,32].
4. Conclusions
In the present study, we have investigated the concept of enhancing insulin permeation by
co-localizing insulin and PE through unidirectional release from MCs. SDS proved more efficient as PE
than C10 and C12-carnitine, increasing insulin permeation across both, Caco-2 cell monolayers and
porcine intestinal tissue. The increased insulin permeation achieved ex vivo did not compromise the
barrier properties towards the apically included pathogen marker, FD70. A combined proteolysis
and permeation study suggested an advantage of including STI in the MCs. However, the MCs did
not increase in vivo insulin absorption upon oral gavage to rats, due to a lack of sufficient retention
and orientation of MCs in the intestinal mucus. Further strategies in order to achieve close proximity
between MCs and enterocytes with optimal unidirectional release in vivo will thus be the focus of
future studies.
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